BIOTRONIK Excellence for Life

At BIOTRONIK, we engineer trusted, life-changing therapies through our advanced active implants in Cardiac Rhythm Management, Monitoring, and Neuromodulation, while providing cutting-edge solutions in Electrophysiology.

The Difference We Make

Highlights

  • Expert Insights on Conduction System Pacing

    Expert-led webinar replays exploring the latest clinical evidence, implantation techniques, and real-world experience with Conductive System Pacing.

    • Clinical insights from experienced electrophysiologists
    • Practical guidance on LBBAP and His Bundle pacing
    • Evidence, outcomes, and case-based discussions
    Get Full Access to Webinar Library
    Conduction System Pacing
  • Uniquely Designed for CSP

    Solia CSP S

    Solia CSP S is the first and only approved1 and proven2 LBBAP lead that combines the advantages of a fixed-screw design with the benefits of a stylet-driven implantation approach - the first ever fixed-screw stylet-driven lead (F-SDL) for CSP.

    Solia CSP S is the industry's only1 lead purpose built for CSP, designed to make CSP procedures both smoother and more accessible for physicians.

    FIND OUT MORE
    Solia CSP S
  • TRANSFORMING CARDIAC CARE THROUGH DIGITAL INNOVATION

    BIOTRONIK Partners with the University of Sydney

    BIOTRONIK and the University of Sydney have signed a Memorandum of Understanding (MoU) to jointly advance digital and connected health innovations through 2028.

    The collaboration aims to co-design solutions that address real-world clinical needs and hopes to benefit patients particularly in remote or underserved regions with limited access to care.

    FIND OUT MORE
    BIOTRONIK-University of Sydney
  • GO RED FOR HEART HEALTH

    Standing Together for Female Cardiac Care!

    Heart disease is the leading cause of death among women worldwide. Yet, women’s heart health is too often overlooked.

    This is why it’s time to put female cardiac care in the spotlight. At BIOTRONIK, we are united in advancing female cardiac care. Join us in our campaign to empower, educate, and lead the change for healthier hearts.

    Follow us on LinkedIn for updates
    Go Red Group

  • Prospera™ Spinal Cord Stimulation System with Embrace One™

    BIOTRONIK Neuro’s Prospera spinal cord stimulation (SCS) system treats patients suffering from chronic pain, helping them embrace life again. The system uniquely features:

    • RESONANCE™, the first and only multiphase stimulation paradigm
    • Embrace One, a truly first-of-its-kind ecosystem that provides automatic, objective, remote daily monitoring

    Prospera SCS System is approved in the US only and is not available outside of the US.

    Note: Embrace One is a support platform intended to help manage a patient’s experience with spinal cord stimulation. It is not intended to be used for medical diagnosis or medical treatment.

    Find out more
    Prospera™ Spinal Cord Stimulation System

    Press Releases

    Visit our Newsroom
    BERLIN, Germany
    Press Release

    First European Implants of BIOTRONIK Leadless Pacemaker LivIQ

    BIOTRONIK, a global leader in medical technology, today announced the first European implantations of its LivIQ leadless pacemaker system as part of the BIO-LivIQ study. The study’s objective is to evaluate the safety and efficacy of LivIQ, including its ability to deliver atrioventricular (AV) synchronous pacing. By enabling AV synchrony at rest and during exercise, LivIQ aims to better address real‑world patient needs, potentially benefiting a broader group of patients, including younger and more active individuals. The procedures were performed by Prof. Christophe Garweg, BIO-LivIQ Steering
    BERLIN, Germany
    Press Release

    Bringing Digital Innovation from Lab to Life in Cardiology

    BIOTRONIK, Charité – Universitätsmedizin Berlin, and the German Heart Center Foundation today announced a research and innovation partnership focused on advancing digital and translational cardiology. The collaboration will bring together world-class clinical cardiovascular expertise at Deutsches Herzzentrum der Charité (DHZC) with BIOTRONIK’s strength in active cardiac devices, artificial intelligence, and connected health technologies. The partnership builds on existing projects in cardiovascular healthcare, including publicly funded initiatives. The cooperation framework will span from
    PARIS, France
    Press Release

    New Analysis from BIO‑LIBRA Highlights Impact of Modern Heart Failure Therapy on Arrhythmic and Mortality Risk

    Late-breaking results from the sex‑balanced, BIOTRONIK-funded study presented at EHRA 2026 Data shows associations between contemporary guideline-directed therapies and improved outcomes in patients with non‑ischemic cardiomyopathy PARIS, France – In a late-breaking trial session at the European Heart Rhythm Association (EHRA) 2026 Congress, principal investigator Valentina Kutyifa, MD, PhD, presented new data from the prospective, sex‑balanced BIO‑LIBRA study. The analysis shows that modern guideline-directed medical therapy (GDMT)—specifically angiotensin receptor–neprilysin inhibitors (ARNI

    We Take Our Responsibility Seriously

    Advancing Health and Well-Being Since 1963

    BIOTRONIK is proud of its 60-year history of life-changing innovations and service to the healthcare community. ​

    The development of the first German pacemaker in 1963 laid the foundation for who we are today. Read more about our journey from pioneer to global leader.

    Explore Our History
    Devices from old to new

    Making a Difference with Heart

    Corporate responsibility is an integral part of who we are and how we do business. We understand that our success is also measured by the positive impact we have on society, the environment, and the well-being of patients and our employees. ​

    This is why we are committed to continually improving and setting higher standards in these crucial areas. 

    Discover Our Commitment to Responsibility
    Young employees talk to each other